Jul 3, 2012
IBA Molecular, Novation sign agreement for PET radiotracers
DULLES, VIRGINIA, 2 July 2012 – IBA Molecular North America, Inc. (IBA Molecular) announced the signing of a 5-year agreement with Novation, a leading health care supply chain expertise and contracting company, to offer PET radiopharmaceuticals, including 18F-Fluorodeoxyglucose (FDG), a diagnostic radiotracer used in oncology, neurology and cardiology, to imaging centers across the country. Novation provides sourcing services, as well as information and data services to a broad range of healthcare providers in the United States.
In addition to providing radioisotopes to member sites served by Novation, IBA Molecular will offer its wide range of PET education and support programs, unique in the industry. The company’s commitment to improved quality in molecular imaging is reflected in the educational resources and programs which it has developed. Creating customized action plans in education, service enhancement and outreach, IBA Molecular assists imaging programs in increasing their impact and value in the medical community. The ultimate goal is to help ensure that each patient receives the correct diagnosis and effective treatment at the appropriate time.
Lee Karras, President of IBA Molecular, noted “We are excited to continue our relationship with Novation, providing outstanding value and support to the member sites it serves, and helping them deliver effective and efficient diagnostic services to the medical community.”
The agreement commenced on July 1, 2012, and will be in place for a period of five years.
About IBA Molecular North America, Inc.
IBA Molecular North America, Inc. is part of IBA Molecular, a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.
Please visit http://www.iba-molecular.com for more information about IBA Molecular.